+34 963 586 020
  • English
    • English
    • Español
    • عربي

We advise all cancer patients to read this IMPORTANT book about the reality of cancer. CANCER: THE SURPRISING TRUTH. Its author is the prestigious molecular biologist Travis Christofferson. We recommend it for all cancer patients and of course for all physicians and oncologists.

Many of these treatments will require authorization from the Ministry of Health (Spanish Agency for Medicines and Health Products) in order to be administered under the legal figure of ‘COMPASSIONATE USE’.
For this purpose, a dossier will be sent with all the necessary information about the patient, their pathology and the drug to be used, while awaiting authorization for its use.

CANCER: THE SURPRISING TRUTH

Electrochemotherapy (Electroporation)

We have recently incorporated the electrochemotherapy technique (ECT). This treatment combines chemotherapy with the application of electrical currents to treat certain types of cancer.

Reversible Electrochemotherapy involves introducing electrodes into the periphery of the tumor. The electrodes surround the tumor, creating an electric field that opens the pores of the cell membranes. Hence, this phenomenon is known as "reversible electrochemotherapy."

This bioelectrical phenomenon is called electroporation. The pores of the pores of cell membranes (both cancerous and healthy) are opened, so the bleomycin chemotherapy enters 5,000 to 10,000 times more than if we were not applying electroporation. Healthy cells are not in an accelerated cycle of division and reproduction, so the drug will affect the dividing cancer cells, particularly the ones that are dividing cancer cells, particularly those in the S phase of mitosis, where the effect will be much greater. This response occurs in the maximum concentration period following the bleomycin infusion, between 8-40 minutes.

Electrochemotherapy has an objective response rate (ORR) of more than 80%, with a high percentage (between 53% and 86%) of complete responses that persist over time.

According to more recent evaluations, the average efficacy of Electrochemotherapy is around 84%, in contrast to systemic chemotherapy, which in stage IV cancer has response rates of less than 35% when used as monotherapy. Less than 35% when used as monotherapy.

hipertermia

The advantages of Electrochemotherapy include:

Lower toxicity, avoiding or reducing side effects by using lower doses of chemotherapy.

Increased effectiveness: Combining chemotherapy with electrical current can increase the effectiveness of treatment, especially in tumors resistant to conventional chemotherapy and radiotherapy.

Electrochemotherapy can also lead to an abscopal effect, where the localized application of the therapy can trigger an abscopal effect, where the localized application of the therapy can trigger an abscopal effect of therapy can trigger an immune response that positively affects distant tumors in the body.

To be able to treat vertebral lesions that infiltrate the spinal cord and that are practically impossible to resect, achieving a therapeutic option with a response rate of more than 80% thanks to the strategic placement of the electrodes.

In the vast majority of cases, it is an outpatient therapy of short duration, which means that the patient can return home on the same day of treatment.

The effectiveness of Electrochemotherapy also carries over to other deeper cancers, such as:

  • Primary hepatocarcinoma (HCC).
  • Multiple or single liver metastases
  • Cholangiocarcinoma
  • Primary pancreatic cancer that cannot be operated on.

ELECTROCHEMOTHERAPY FOR BONE TUMORS AND METASTASES

Unlike other local treatments for bone lesions, such as radiotherapy or thermal ablation, which can damage the mineralized structure of the bone, Electrochemotherapy has the advantage of not causing irreversible damage to the bone tissue. This allows the bone to heal and preserves its structural integrity.

ELECTROCHEMOTHERAPY FOR LIVER TUMORS

The advantages in treating these neoplasms include high effectiveness, regardless of the type of tumor, and an ablation modality that does not generate heat, minimizing damage to nearby structures such as blood vessels and bile ducts, and useful even in large and irregularly shaped lesions. In addition, it offers wide safety margins and a technique that preserves healthy tissue, allowing biliodigestive anastomosis and prolonged release of tumor antigens. It maintains complete response rates of 50% and partial responses of 30-35%, with an objective response rate (ORR) usually greater than 80%. These responses can significantly improve the patient's quality of life and prolonged survival.

ELECTROCHEMOTHERAPY IN BREAST TUMORS

Electrochemotherapy is a promising option for breast cancer patients, successfully treating lesions such as locoregional recurrences, cutaneous and subcutaneous metastases, ulcerated and/or bleeding lesions where surgery is contraindicated, in the presence of multiple lesions, being used in bulky tumors as neoadjuvant therapy to facilitate future surgery, and being applied to complete surgical resection of the tumor as adjuvant therapy when appropriate margins cannot be achieved.

ELECTROCHEMOTHERAPY IN VULVAR CANCER

Electrochemotherapy is presented as an option for patients not suitable for surgery, lesions resistant to chemo-radiotherapy, and patients with severe comorbidities and/or advanced age. It produces a high response rate, with a significant reduction of pain and improvement of local symptoms.

Dr. Carbonell receiving training at the San Raffaele Hospital in Milan (Italy).

hipertermia hipertermia hipertermia

BIBLIOGRAPHY

Request information without obligation

Request information without obligation, we will study your case with our medical team to give you an answer as soon as possible.

250
I accept the terms of use and privacy policy
mmoncoproject.com
  • Calle Salvador Guinot 14 46017 , Valencia, Valencia. España
  • Tel.: +34 963 586 020
  • Lunes a domingo sin datos
  • Forma de pago:
    sin datos
Calendly